Who Exports Indomethacin from India — 139 Suppliers Behind a $9.4M Market
India's indomethacin export market is supplied by 139 active exporters who collectively shipped $9.4M across 1,248 shipments. HETERO LABS LIMITED leads with a 41.6% market share, followed by GLENMARK PHARMACEUTICALS LIMITED and ZYDUS LIFESCIENCES LIMITED. The top 5 suppliers together control 76.5% of total export value, reflecting a concentrated market structure.
Top Indomethacin Exporters from India — Ranked by Export Value
HETERO LABS LIMITED is the leading indomethacin exporter from India, holding a 41.6% share of the $9.4M market across 1,248 shipments from 139 exporters. The top 5 suppliers — HETERO LABS LIMITED, GLENMARK PHARMACEUTICALS LIMITED, ZYDUS LIFESCIENCES LIMITED, GLENMARK PHARMACEUTICALS LTD, LEBEN LABORATORIES PRIVATE LIMITED — collectively control 76.5% of total export value, indicating a highly concentrated market. Individual shares are: HETERO LABS LIMITED (41.6%), GLENMARK PHARMACEUTICALS LIMITED (16.8%), ZYDUS LIFESCIENCES LIMITED (7.0%), GLENMARK PHARMACEUTICALS LTD (6.6%), LEBEN LABORATORIES PRIVATE LIMITED (4.5%).
Top Indomethacin Exporters from India
Ranked by export value · 139 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | HETERO LABS LIMITED INDOMETHACIN CAPSULEINDOMETHACIN SUPPOSITORIES USP 50MG [2496 PACK X 5X6]INDOMETHACIN CAPS | $3.9M | 3 | 41.6% |
| 2 | GLENMARK PHARMACEUTICALS LIMITED INDOMETHACIN CAPSULEINDOMETHACIN SUPPOSITORIES USP 50MG [2496 PACK X 5X6]INDOMETHACIN CAPS | $1.6M | 4 | 16.8% |
| 3 | ZYDUS LIFESCIENCES LIMITED INDOMETHACIN CAPSULEINDOMETHACIN SUPPOSITORIES USP 50MG [2496 PACK X 5X6]INDOMETHACIN CAPS | $657.5K | 2 | 7.0% |
| 4 | GLENMARK PHARMACEUTICALS LTD INDOMETHACIN CAPSULEINDOMETHACIN SUPPOSITORIES USP 50MG [2496 PACK X 5X6]INDOMETHACIN CAPS | $618.0K | 1 | 6.6% |
| 5 | LEBEN LABORATORIES PRIVATE LIMITED INDOMETHACIN-25 BL.INDOMETHACIN-2PHARMACEUTICAL PRODUCTS - INDOMETHACIN CAPSULES BP 25MG | $419.7K | 6 | 4.5% |
| 6 | CADILA HEALTHCARE LIMITED INDOMETHACIN CAPSULEINDOMETHACIN SUPPOSITORIES USP 50MG [2496 PACK X 5X6]INDOMETHACIN CAPS | $287.5K | 1 | 3.1% |
| 7 | MERIDIAN ENTERPRISES PRIVATE LIMITED HARMLESS MEDICINES. INDOMETHACIN SUPPOSIHARMLESS MEDICINES : INDOMETHACIN SUPPOSITORIES 100MGINDOMETHACIN SUPPOSITORIES USP 100 MG PACK SIZE- 20X5 NOS | $205.3K | 2 | 2.2% |
| 8 | ANGEL REMEDIES INDOMETHACIN CAPS 25MG (PRODUCT NAMEIND | $187.7K | 1 | 2.0% |
| 9 | SCOTT EDIL PHARMACIA LIMITED INDOMETHACIN-25 BL.INDOMETHACIN-2INDOMETHACIN CAPS 25MG (PRODUCT NAMEINDPHARMACEUTICAL PRODUCTS - INDOMETHACIN CAPSULES BP 25MG | $154.1K | 3 | 1.6% |
| 10 | AFRICURE PHARMACEUTICALS (INDIA) PRIVATELIMITED INDOMETHACIN-25 BL.INDOMETHACIN-2PHARMACEUTICAL PRODUCTS - INDOMETHACIN CAPSULES BP 25MG | $102.5K | 3 | 1.1% |
| 11 | UMEDICA LABORATORIES PRIVATE LIMITED | $91.6K | 3 | 1.0% |
| 12 | DEN MARK PHARMACEUTICALS PRIVATE LIMITED INDOMETHACINE OINTMENT 30G (INDOMETACIN | $88.8K | 1 | 0.9% |
| 13 | USAN PHARMACEUTICALS PRIVATE LIMITED INDOM - 75 MG INDOMETHACIN CAPSULES USP75 MG AS PER INV | $80.5K | 1 | 0.9% |
| 14 | LABORATE PHARMACEUTICALS INDIA LIMITED INDOMETHACINE OINTMENT 30G (INDOMETACIN | $61.8K | 1 | 0.7% |
| 15 | GENEX PHARMA | $51.5K | 4 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Indomethacin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Approved | Yes | Yes | Multiple | Formerly known as Cadila Healthcare Limited; engaged in manufacturing generic dr |
| Glenmark Pharmaceuticals Limited | Warning Letter (July 2025 | Yes | Yes | Multiple | Received multiple FDA warning letters; latest in July 2025 for Madhya Pradesh fa |
| Cadila Pharmaceuticals Limited | Warning Letter (October 2 | Yes | Yes | Multiple | Received FDA warning letter in October 2019 for Moraiya and Ahmedabad plants. |
TransData Nexus reviewed the regulatory standing of 3 leading Indomethacin exporters from India. 1 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Indomethacin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for Active Pharmaceutical Ingredients (APIs) production. The city hosts numerous API manufacturers, contributing significantly to India's pharmaceutical exports. Companies like Hetero Labs Limited, headquartered in Hyderabad, are prominent players in this sector. Hetero Labs Limited accounted for 41.6% of Indomethacin exports, amounting to $3.9 million, between 2022 and 2026. The city's infrastructure, skilled workforce, and supportive government policies have fostered a conducive environment for bulk drug manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to leading companies such as Zydus Lifesciences Limited and Cadila Pharmaceuticals. Zydus Lifesciences Limited contributed 7.0% ($0.7 million) to Indomethacin exports, while Cadila Healthcare Limited accounted for 3.1% ($0.3 million) during the same period. The presence of these companies underscores the region's strength in producing finished pharmaceutical products. The cluster benefits from a robust industrial ecosystem, including research and development facilities, which support the development and manufacturing of diverse pharmaceutical formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. Companies like Glenmark Pharmaceuticals Limited, headquartered in Mumbai, play a significant role in this cluster. Glenmark Pharmaceuticals Limited contributed 16.8% ($1.6 million) to Indomethacin exports between 2022 and 2026. The region's strategic location, coupled with well-established logistics and regulatory infrastructure, enhances its capacity to serve international markets efficiently.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing hub, largely due to favorable tax incentives and supportive government policies. This cluster hosts numerous pharmaceutical companies, including Scott Edil Pharmacia Limited, which accounted for 1.6% ($0.2 million) of Indomethacin exports between 2022 and 2026. The region's growth is attributed to its cost-effective production capabilities and proximity to key markets in North India.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with over-reliance on a single supplier, consider engaging with multiple manufacturers across different clusters.
- Evaluate Supplier Capabilities: Assess the technical capabilities, regulatory compliance, and quality standards of potential suppliers to ensure consistent product quality.
- Leverage Regional Strengths: Utilize the specific strengths of each pharmaceutical cluster, such as API production in Hyderabad or formulations in Ahmedabad-Vadodara, to optimize the supply chain.
- Monitor Export Trends: Stay informed about export data and market dynamics to identify emerging suppliers and adjust sourcing strategies accordingly.
By strategically sourcing from India's diverse pharmaceutical clusters, companies can enhance supply chain resilience and capitalize on the country's robust manufacturing capabilities.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Indomethacin exporters from India
Glenmark Pharmaceuticals Limited — Glenmark acquires Acetylcysteine injection ANDA from Aspen Pharma
In March 2025, Glenmark Pharmaceuticals, through its subsidiary, acquired the Abbreviated New Drug Application (ANDA) for Acetylcysteine injection, 6 gm/30 mL (200 mg/mL) single-dose vials from Aspen Pharma USA Inc., expanding its injectables portfolio. - IMPACT: This acquisition enhances Glenmark's injectables portfolio, potentially increasing its production capacity and export capabilities, including for Indomethacin.
Impact: This acquisition enhances Glenmark's injectables portfolio, potentially increasing its production capacity and export capabilities, including for Indomethacin.
Zydus Lifesciences Limited — Zydus establishes Zydus MedTech (France) SAS
In April 2025, Zydus Lifesciences announced the incorporation of a wholly owned subsidiary, Zydus MedTech (France) SAS, in France, aiming to acquire equity shares of Amplitude Surgical SA. - IMPACT: This strategic move may enhance Zydus's European market presence, potentially boosting Indomethacin exports to the region.
Impact: This strategic move may enhance Zydus's European market presence, potentially boosting Indomethacin exports to the region.
Glenmark Pharmaceuticals Limited — Glenmark sells 75% stake in Glenmark Life Sciences to Nirma
In July 2025, Glenmark completed the divestment of a 75% stake in Glenmark Life Sciences to Nirma Limited for approximately ₹5,651 crore, aiming to reduce debt and focus on its core innovative pipeline. - IMPACT: This divestment may lead to a strategic realignment, potentially affecting Glenmark's production and export strategies, including for Indomethacin.
Impact: This divestment may lead to a strategic realignment, potentially affecting Glenmark's production and export strategies, including for Indomethacin.
Common Questions — Indomethacin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which indomethacin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, HETERO LABS LIMITED leads with 144 recorded shipments worth $3.9M. GLENMARK PHARMACEUTICALS LIMITED (112 shipments) and ZYDUS LIFESCIENCES LIMITED (13 shipments) are also established high-volume exporters.
Q How many indomethacin manufacturers are there in India?
India has 139 active indomethacin exporters with a combined export market of $9.4M across 1,248 shipments to 70 countries. The top 5 suppliers hold 76.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for indomethacin from India?
Average FOB unit price: $3.86 per unit, ranging from $0.00 to $61.92. Average shipment value: $7.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 139 verified Indian exporters of Indomethacin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,248 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 70 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,248 Verified Shipments
139 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists